Clinical Context
Diabetic peripheral neuropathy (DPN) affects approximately 50% of patients with diabetes during their lifetime and is the leading cause of non-traumatic lower limb amputations. The condition manifests as numbness, tingling, burning pain, and loss of protective sensation in a “stocking-glove” distribution, progressively impacting quality of life and increasing fall risk. Despite its prevalence, treatment options for DPN remain limited, with current therapies focusing on symptomatic relief (gabapentin, pregabalin, duloxetine) rather than disease modification.
Glycemic control is the only established intervention that can prevent or slow DPN progression, yet even with intensive glucose management, many patients develop neuropathy. This has spurred interest in whether specific glucose-lowering agents might offer neuroprotective benefits beyond their glycemic effects. SGLT2 inhibitors have demonstrated pleiotropic benefits including cardiovascular and renal protection, raising the question of whether similar benefits might extend to the peripheral nervous system.
Proposed mechanisms for potential SGLT2i neuroprotection include reduced oxidative stress through decreased glucotoxicity, improved microvascular blood flow, reduced inflammation, and direct effects on neuronal metabolism. This study directly tests whether adding empagliflozin improves objective markers of nerve function in patients with established diabetic neuropathy.
Study Summary (PICO Framework)
Summary:
In patients with type 2 diabetes and peripheral neuropathy, adding empagliflozin to the medication regimen significantly improved blood glucose control, kidney filtration function, and nerve conduction velocity compared to standard treatment without empagliflozin, though detailed side effect data were not reported.
| PICO | Description |
|---|---|
| Population | Patients with type 2 diabetes experiencing peripheral neuropathy. |
| Intervention | Addition of empagliflozin to existing diabetic medication regimen. |
| Comparison | Standard diabetic medication regimen without empagliflozin. |
| Outcome | Improved glycemic control, kidney function, clinical symptoms, and nerve conduction velocity with empagliflozin addition. |
Clinical Pearls
1. Nerve conduction velocity improvement is an objective, disease-modifying outcome. Unlike symptomatic endpoints (pain scores, quality of life), nerve conduction velocity directly measures peripheral nerve function. Improvement in NCV suggests actual restoration of nerve physiology rather than merely masking symptoms—a distinction that has important implications for long-term outcomes and amputation prevention.
2. Multiple mechanisms may contribute to benefit. SGLT2 inhibitors improve glucose control, which itself protects nerves from glucotoxicity. Additionally, empagliflozin’s renal protective effects may reduce uremic toxins that contribute to neuropathy in diabetic kidney disease. The improvement in kidney filtration function observed in this study may independently benefit peripheral nerves.
3. This adds to SGLT2i’s growing list of pleiotropic benefits. Beyond cardiovascular protection (EMPA-REG OUTCOME), heart failure benefit (EMPEROR-Preserved/Reduced), and kidney protection (CREDENCE, DAPA-CKD), potential neuroprotective effects would further expand the indications for SGLT2 inhibitor use in diabetes.
4. Early intervention may be key. If SGLT2 inhibitors can slow or reverse early neuropathy, initiating these agents before advanced nerve damage occurs may maximize benefit. This supports current guideline recommendations for SGLT2i as foundational therapy in type 2 diabetes, not reserved for later-stage disease.
Practical Application
Patient selection: Consider empagliflozin for patients with type 2 diabetes and early-to-moderate DPN, particularly those with concomitant cardiovascular disease, heart failure, or chronic kidney disease where SGLT2i benefits are already established. Patients with advanced neuropathy and complete sensory loss may have less reversible nerve damage.
Assessment before and after treatment: Document baseline neuropathy status using standardized tools such as the Michigan Neuropathy Screening Instrument (MNSI), monofilament testing, or formal nerve conduction studies if available. Reassess symptoms and objective findings at 3-6 month intervals to gauge response.
Dosing: Empagliflozin is typically started at 10 mg daily, which can be increased to 25 mg for additional glycemic benefit. No dose adjustment is needed for mild-to-moderate kidney impairment, though the drug should not be initiated if eGFR is below 20-30 mL/min (varies by indication).
Managing expectations: Counsel patients that neuropathy improvement, if it occurs, will be gradual over months. SGLT2 inhibitors are not a substitute for good glycemic control, blood pressure management, and foot care. They should be viewed as part of comprehensive diabetes management rather than a standalone neuropathy treatment.
How This Study Fits Into the Broader Evidence
This study adds to a growing body of observational and mechanistic data suggesting SGLT2 inhibitors may benefit diabetic neuropathy. A Korean registry study found lower rates of DPN progression in SGLT2i users. Preclinical studies in diabetic rodent models have shown improved nerve function with SGLT2 inhibition. The EMPA-REG OUTCOME trial showed trends toward reduced peripheral neuropathy events, though this was not a prespecified endpoint.
Current ADA and EASD guidelines recommend SGLT2 inhibitors as first-line therapy for patients with type 2 diabetes and established atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease. These recommendations are based on cardiovascular and renal outcome data. If neuroprotective benefits are confirmed in larger trials, DPN could become another indication for preferential SGLT2i use.
Ongoing research, including dedicated neuropathy trials with SGLT2 inhibitors, will help clarify whether these agents should be specifically recommended for diabetic neuropathy prevention or treatment.
Limitations to Consider
The study details available are limited, including sample size, treatment duration, specific outcome magnitudes, and the complete safety profile. The randomized, double-blind design is a strength, but without knowing effect sizes, it’s difficult to assess clinical significance versus statistical significance. The findings require confirmation in larger, longer-term trials with well-defined neuropathy endpoints.
Bottom Line
Adding empagliflozin to existing diabetes therapy appears to improve both symptoms and objective nerve conduction measures in patients with diabetic peripheral neuropathy. While this doesn’t yet establish SGLT2 inhibitors as a neuropathy treatment per se, it provides another reason to preferentially use these agents in patients with type 2 diabetes—particularly those with or at risk for microvascular complications. Given SGLT2i’s established cardiovascular and renal benefits, potential neuroprotection is a welcome bonus.
Source: Mohammadreza Vafaeinasab, et al. “The Comparison of the Effect of Adding Empagliflozin to the Medication Regimen on Peripheral Neuropathy in Patients With Type II Diabetes: A Double Blind Randomised Clinical Trial.” Read article here.
